RU2013133803A - Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп - Google Patents
Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп Download PDFInfo
- Publication number
- RU2013133803A RU2013133803A RU2013133803/15A RU2013133803A RU2013133803A RU 2013133803 A RU2013133803 A RU 2013133803A RU 2013133803/15 A RU2013133803/15 A RU 2013133803/15A RU 2013133803 A RU2013133803 A RU 2013133803A RU 2013133803 A RU2013133803 A RU 2013133803A
- Authority
- RU
- Russia
- Prior art keywords
- glp
- peptide
- life
- hip
- prolonged half
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426338P | 2010-12-22 | 2010-12-22 | |
| US61/426,338 | 2010-12-22 | ||
| US201161500229P | 2011-06-23 | 2011-06-23 | |
| US61/500,229 | 2011-06-23 | ||
| PCT/US2011/066739 WO2012088379A2 (en) | 2010-12-22 | 2011-12-22 | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013133803A true RU2013133803A (ru) | 2015-01-27 |
Family
ID=46314922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013133803/15A RU2013133803A (ru) | 2010-12-22 | 2011-12-22 | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8975223B2 (https=) |
| EP (1) | EP2654774A4 (https=) |
| JP (1) | JP2014501762A (https=) |
| KR (1) | KR20140020851A (https=) |
| CN (1) | CN103402536A (https=) |
| AR (1) | AR084558A1 (https=) |
| AU (1) | AU2011348202A1 (https=) |
| BR (1) | BR112013015861A2 (https=) |
| CA (1) | CA2822617A1 (https=) |
| MX (1) | MX2013007327A (https=) |
| NZ (1) | NZ611878A (https=) |
| RU (1) | RU2013133803A (https=) |
| SG (1) | SG191252A1 (https=) |
| WO (1) | WO2012088379A2 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2528618A4 (en) * | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| PE20240686A1 (es) | 2011-06-10 | 2024-04-10 | Hanmi Science Co Ltd | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) |
| PE20230404A1 (es) | 2011-06-17 | 2023-03-07 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| RU2610175C2 (ru) | 2011-09-23 | 2017-02-08 | Ново Нордиск А/С | Новые аналоги глюкагона |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PE20151421A1 (es) | 2012-11-06 | 2015-09-24 | Hanmi Pharm Ind Co Ltd | Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| HK1214832A1 (zh) | 2012-11-28 | 2016-08-05 | 恩格姆生物制药公司 | 用於代謝病症和疾病治療的組合物和方法 |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| MX383664B (es) | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
| SI2986313T1 (sl) * | 2013-04-18 | 2019-09-30 | Novo Nordisk A/S | Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo |
| LT3004155T (lt) * | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| WO2015035419A1 (en) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
| CN105792851B (zh) * | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| WO2015065897A1 (en) | 2013-10-28 | 2015-05-07 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
| CN112043835B (zh) | 2013-12-06 | 2022-10-21 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| PT3097122T (pt) | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CA2952905A1 (en) * | 2014-08-06 | 2016-02-11 | Nestec S.A. | Biomarkers for predicting degree of weight loss |
| US10968266B2 (en) | 2014-09-05 | 2021-04-06 | University Of Copenhagen | GIP peptide analogues |
| TWI802396B (zh) * | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| CN114129709A (zh) | 2014-10-23 | 2022-03-04 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CR20170164A (es) | 2014-10-24 | 2017-08-29 | Merck Sharp & Dohme | Coagonistas de los receptores de glucagón y de glp-1 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| JO3575B1 (ar) * | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| KR101669140B1 (ko) | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| AR107890A1 (es) * | 2016-03-10 | 2018-06-28 | Medimmune Ltd | Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| CN109200273B (zh) * | 2017-07-04 | 2021-02-19 | 中国药科大学 | 一种多肽用于制备预防或治疗脂肪肝病药物的用途 |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| PL3630806T3 (pl) * | 2017-05-31 | 2024-05-13 | The University Of Copenhagen | Analogi peptydów gip o długotrwałym działaniu |
| US10470311B2 (en) * | 2017-09-28 | 2019-11-05 | Juniper Networks, Inc. | Clearance size reduction for backdrilled differential vias |
| JP7148605B2 (ja) | 2017-10-12 | 2022-10-05 | ノヴォ ノルディスク アー／エス | 医学療法におけるセマグルチド |
| KR102379958B1 (ko) * | 2018-05-04 | 2022-04-01 | 노보 노르디스크 에이/에스 | Gip 유도체 및 이의 용도 |
| CN120754229A (zh) * | 2018-07-23 | 2025-10-10 | 伊莱利利公司 | 使用gip/glp1共激动剂用于治疗的方法 |
| CN121449721A (zh) | 2018-12-03 | 2026-02-03 | 安泰博医药 | 经修饰的gip肽类似物 |
| CN109379770B (zh) * | 2018-12-11 | 2021-04-06 | 北京百瑞互联技术有限公司 | 蓝牙mesh网络的路径辅助候选节点的优选方法、装置及节点 |
| AU2020206388B2 (en) * | 2019-01-07 | 2022-12-01 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic uses thereof |
| WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
| AU2020397917A1 (en) | 2019-12-04 | 2022-06-23 | The Scripps Research Institute | GLP2 receptor agonists and methods of use |
| WO2021169512A1 (zh) * | 2020-02-24 | 2021-09-02 | 中山大学 | 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用 |
| CN116113429A (zh) * | 2020-07-06 | 2023-05-12 | 鸿绪生物医药科技（北京）有限公司 | 新型多肽及其治疗用途 |
| MX2023000303A (es) * | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
| BR112023000229A2 (pt) * | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
| MX2023001599A (es) * | 2020-08-14 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip. |
| WO2022080986A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| EP4257597A4 (en) * | 2020-12-02 | 2025-04-02 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS |
| CN114891071A (zh) * | 2020-12-08 | 2022-08-12 | 鸿绪生物科技(嘉善)有限公司 | 新型多肽及其治疗用途 |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| IL308392A (en) | 2021-05-13 | 2024-01-01 | Carmot Therapeutics Inc | G protein-coupled receptor modulators |
| MX2023014771A (es) * | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
| CA3237796A1 (en) * | 2021-11-12 | 2023-05-19 | Zhenbin Li | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN116143884B (zh) * | 2023-02-03 | 2023-08-04 | 江苏师范大学 | 一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用 |
| KR20260005268A (ko) * | 2023-04-23 | 2026-01-09 | 카모트 테라퓨틱스 인크. | 당뇨병 치료 |
| WO2026046202A1 (zh) * | 2024-08-26 | 2026-03-05 | 博瑞生物医药（苏州）股份有限公司 | Glp-1/gip肽或含有其的药物组合物的用途 |
| WO2026046328A1 (en) * | 2024-08-30 | 2026-03-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Dosing regimen of glp-1 conjugates |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US8933197B2 (en) | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| DK2300035T3 (en) * | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
-
2011
- 2011-12-22 SG SG2013047402A patent/SG191252A1/en unknown
- 2011-12-22 CA CA2822617A patent/CA2822617A1/en not_active Abandoned
- 2011-12-22 JP JP2013546407A patent/JP2014501762A/ja active Pending
- 2011-12-22 KR KR1020137019021A patent/KR20140020851A/ko not_active Withdrawn
- 2011-12-22 WO PCT/US2011/066739 patent/WO2012088379A2/en not_active Ceased
- 2011-12-22 MX MX2013007327A patent/MX2013007327A/es not_active Application Discontinuation
- 2011-12-22 US US13/996,937 patent/US8975223B2/en not_active Expired - Fee Related
- 2011-12-22 EP EP11851411.6A patent/EP2654774A4/en not_active Withdrawn
- 2011-12-22 AU AU2011348202A patent/AU2011348202A1/en not_active Abandoned
- 2011-12-22 CN CN2011800619016A patent/CN103402536A/zh active Pending
- 2011-12-22 BR BR112013015861A patent/BR112013015861A2/pt not_active IP Right Cessation
- 2011-12-22 AR ARP110104906A patent/AR084558A1/es unknown
- 2011-12-22 NZ NZ611878A patent/NZ611878A/en not_active IP Right Cessation
- 2011-12-22 RU RU2013133803/15A patent/RU2013133803A/ru not_active Application Discontinuation
-
2015
- 2015-02-10 US US14/618,580 patent/US20160175400A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ611878A (en) | 2015-02-27 |
| WO2012088379A2 (en) | 2012-06-28 |
| KR20140020851A (ko) | 2014-02-19 |
| SG191252A1 (en) | 2013-07-31 |
| CN103402536A (zh) | 2013-11-20 |
| AU2011348202A1 (en) | 2013-07-04 |
| US20140018291A1 (en) | 2014-01-16 |
| WO2012088379A9 (en) | 2012-11-08 |
| BR112013015861A2 (pt) | 2018-06-05 |
| AR084558A1 (es) | 2013-05-22 |
| MX2013007327A (es) | 2014-01-08 |
| CA2822617A1 (en) | 2012-06-28 |
| US20160175400A1 (en) | 2016-06-23 |
| JP2014501762A (ja) | 2014-01-23 |
| AU2011348202A9 (en) | 2016-03-24 |
| US8975223B2 (en) | 2015-03-10 |
| EP2654774A2 (en) | 2013-10-30 |
| EP2654774A4 (en) | 2015-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013133803A (ru) | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп | |
| JP2014501762A5 (https=) | ||
| CA2740685C (en) | Combination of an insulin and a glp-1 agonist | |
| US20220152160A1 (en) | Dosing regimen | |
| RU2015101826A (ru) | Применение долгодействующих пептидов glp-1 | |
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| RU2011109016A (ru) | Применение сверхбыстродействующего инсулина | |
| KR20130139297A (ko) | 다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료 | |
| RU2012124069A (ru) | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин | |
| US11116820B2 (en) | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives | |
| EP3978011A1 (en) | Treatment of post-bariatric hypoglycemia with glp-1 antagonists | |
| WO2003105897A1 (en) | Combined use of a modulator of cd3 and a glp-1 compound | |
| KR20250029908A (ko) | 티르제파티드 조성물 및 용도 | |
| Woo | A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus | |
| EP3762017B1 (en) | Glp-1 analogue beinaglutide composition for treating obesity and weight management | |
| JP6049625B2 (ja) | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 | |
| WO2021143879A1 (en) | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs | |
| AU2024311368A1 (en) | Glp-1 analog for use in the treatment of metabolic disorders | |
| Gallwitz | Glucagon-like peptide-1 receptor agonists | |
| US20210213104A1 (en) | Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes | |
| HK40031313A (en) | Combination of an insulin and a glp-1 agonist | |
| HK40031313B (en) | Combination of an insulin and a glp-1 agonist | |
| HK1244701B (en) | Combination of an insulin and a glp-1 agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160603 |